IGC Pharma, Inc. announced on February 11, 2025, the launch of Holiby™, a new wellness brand offering scientifically formulated products for immune defense and sustained energy. This strategic expansion marks the company's entry into the rapidly growing $75 billion wellness industry.
The launch of Holiby™ establishes a new revenue stream for IGC Pharma, complementing its ongoing pharmaceutical pipeline focused on treatments for Alzheimer's disease and metabolic disorders. This diversification leverages the company's state-of-the-art manufacturing facility.
This strategic move aims to provide a non-dilutive source of revenue, which is crucial for a clinical-stage biotechnology company. By tapping into the broad wellness market, IGC Pharma seeks to build a more robust and diversified business model.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.